Cingulate Inc CING:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/30/22 EDT
1.10quote price arrow up+0.03 (+2.80%)
Volume
410
Close
1.07quote price arrow up+0.03 (+2.88%)
Volume
4,007
52 week range
0.94 - 5.15
Loading...
  • Open1.07
  • Day High1.11
  • Day Low1.07
  • Prev Close1.04
  • 52 Week High5.15
  • 52 Week High Date12/08/21
  • 52 Week Low0.94
  • 52 Week Low Date09/26/22

Key Stats

  • Market Cap12.10M
  • Shares Out11.31M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-61.23

KEY STATS

  • Open1.07
  • Day High1.11
  • Day Low1.07
  • Prev Close1.04
  • 52 Week High5.15
  • 52 Week High Date12/08/21
  • 52 Week Low0.94
  • 52 Week Low Date09/26/22
  • Market Cap12.10M
  • Shares Out11.31M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-61.23

RATIOS/PROFITABILITY

  • EPS (TTM)-3.46
  • P/E (TTM)-0.31
  • Fwd P/E (NTM)-0.83
  • EBITDA (TTM)-26.015M
  • ROE (TTM)-383.23%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.37%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cingulate Inc

 

Profile

MORE
Cingulate Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The...
Shane Schaffer Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Laurie Myers Ph.D.
Chief Operating Officer, Executive Vice President
Louis Van Horn
Chief Financial Officer, Executive Vice President
Address
1901 W. 47Th Place
Kansas City, KS
66205
United States